AstraZeneca PLC · LSE:AZN
AstraZeneca — Investor Presentation (1999)
13 slides from AstraZeneca's investor presentation, 1999
Slide 1: AstraZeneca Pain Control
AstraZeneca Pain Control Carl-Johan Dalsgaard Vice President & Head of Pain TA Vision h Maintain and develop leadership in anaesthesia h Novel therapies in analgesia meeting high unmet medical needs h Focus on nociceptive and neuropathic pain Leading company in pain control worldwide
Slide 2: An anaesthesia portfolio that meets market trends
An anaesthesia portfolio that meets market trends LA h AstraZeneca has 40% market share GA injection h The trends are – increased day case surgery – early mobilisation GA NMBs inhalation – increased use of i.v. and regional anaesthetics Total value $2.8bn Diprivan® - the leading i.v. anaesthetic Def
Slide 3: Naropin - first single enantiomer in local anaesthesia
Diprivan® EDTA Slide unpublished Naropin® - first single enantiomer in local anaesthesia Approved in 50 countries, launched in 38 Product development through sNDAs 1999 2000 2001 ® Naropin ® Naropin Naropin ® ® Japan Naropin spinal, paediatric Naropin ® paediatric continuous 0-12 years 72h post-op 1
Slide 4: Naropin opportunities in pain control
Naropin® opportunities in pain control Satisfactory pain control after major abdominal surgery 70% with 90% with Naropin Naropin® alone ® + fentanyl Naropin® opportunities in pain control Satisfactory pain control after major abdominal surgery 70% with 90% with Naropin Naropin® alone ® + fentanyl Ea
Slide 5: Naropin opportunities in pain control
Naropin® opportunities in pain control Satisfactory pain control after major abdominal surgery 70% with 90% with Naropin Naropin® alone ® + fentanyl Earlier mobilisation possible with Naropin® compared to bupivacaine after major abdominal surgery Statistically All Naropin®significant difference pati
Slide 6: Naropin shows less cardiotoxicity than levobupivacaine
Naropin® shows less cardiotoxicity than levobupivacaine Resuscitation after cardiovascular collapse in the dog Plasma conc Ventricular Death at cardiovascular fibrillation during collapse (µg/ml) resuscitation Naropin® 38 0/10 1/10 levobupivacaine 24 2/10 3/10 bupivacaine 22 4/10 5/10 Increased toxi
Slide 7: Opportunities in analgesia
Opportunities in analgesia Acute pain OA&RA OA&RA Acute pain Back pain Back pain Cancer pain Other Other Cancer pain Neuropathic Migraine Neuropathic Migraine 1998: $14.5bn 2008: $30bn Innovative approaches to the 3 key medical needs of analgesia h Strong analgesic without opioid side effects h Effe
Slide 8: Innovative approaches to the key medical needs of analgesia
Innovative approaches to the 3 key medical needs of analgesia h Strong analgesic without opioid side effects LEF h Effective treatment for neuropathic pain EP1 h Effective NSAID without GI side effects NO-NSAID LEF - strong analgesic without opioid side effects h Peripheral µ-opioid analgesia withou
Slide 9: LEF does not pass blood brain barrier in man
LEF does not pass blood brain barrier in man Peripheral effect (Prolactin release) Central effect (Miotic response) ug/l mm2 20 25 15 20 15 10 10 5 5 0 0 1 5 25 75 250 -5 1 5 25 75 250 Dose (nmol/kg) Dose (nmol/kg) LEF Morphine EP-1 antagonist for treatment of neuropathic pain Blocks central prostag
Slide 10: EP-1 antagonist blocks central sensitisation
EP-1 antagonist blocks central sensitisation Pain thresholds in human volunteer model 10 Threshold change 5 0 EP-1 0 0.5 1 1.5 2 Vehicle -5 Control -10 -15 Hours NO-NSAID - a unique approach to nociceptive pain Both COX1 and COX2 inhibition is required for full pain relief in inflammatory conditions
Slide 11: NO-NSAID is more effective than COX2 in the rat
NO-NSAID is more effective than COX2 in the rat Carrageenan arthritis in rat - pain behaviour 3 2.5 Pain score 2 NO-NSAID 1.5 Celecoxib 1 Vehicle * 0.5 0 * p<0.05 vs Vehicle and celecoxib 0 3 4 5 Hours NO-NSAID show good GI tolerability in animals control Naproxen NO-Naproxen Diclofenac
Slide 12: Summary of pain control portfolio (NDAs)
Summary of pain control portfolio (NDAs) 1999 2000 2001 2002 2003 2004 Diprivan® Dental gel LEF (i.v.) EP1 EDTA NO-NSAID LEF Naropin® (non-parenteral) Naropin® Naropin® 72h post-op paediatric LTA analgesia spinal 1-12 years continuous Naropin® nerve block Japan Naropin® Naropin® paediatric intra-art
Slide 13: Slide 13